标题
Drug discovery targeting the mTOR pathway
作者
关键词
-
出版物
CLINICAL SCIENCE
Volume 132, Issue 5, Pages 543-568
出版商
Portland Press Ltd.
发表日期
2018-03-10
DOI
10.1042/cs20171158
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Connecting chaperone-mediated autophagy dysfunction to cellular senescence
- (2018) Daniel Moreno-Blas et al. AGEING RESEARCH REVIEWS
- Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572
- (2018) David Schiff et al. CANCER
- mTORC1 Signaling: A Double-Edged Sword in Diabetic β Cells
- (2018) Amin Ardestani et al. Cell Metabolism
- Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study
- (2018) Glenn J. Hanna et al. CLINICAL CANCER RESEARCH
- FLCN : The causative gene for Birt-Hogg-Dubé syndrome
- (2018) Laura S. Schmidt et al. GENE
- Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
- (2017) Christophe Massard et al. EUROPEAN JOURNAL OF CANCER
- Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma
- (2017) P. Penttilä et al. EUROPEAN JOURNAL OF CANCER
- Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1
- (2017) Hui Li et al. HEPATOLOGY
- Tuberous sclerosis complex: Recent advances in manifestations and therapy
- (2017) Mari Wataya-Kaneda et al. INTERNATIONAL JOURNAL OF UROLOGY
- Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer
- (2017) Zongbi Yi et al. Journal of Breast Cancer
- PtdIns3P controls mTORC1 signaling through lysosomal positioning
- (2017) Zhi Hong et al. JOURNAL OF CELL BIOLOGY
- Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy
- (2017) P. S. Chowdhury et al. JOURNAL OF INTERNAL MEDICINE
- Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR -Activating Mutation
- (2017) Juan Francisco Rodríguez-Moreno et al. Journal of the National Comprehensive Cancer Network
- Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial
- (2017) Hope S Rugo et al. LANCET ONCOLOGY
- Targeting metabolism in cellular senescence, a role for intervention
- (2017) Timothy Nacarelli et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph + and Ph-like B-ALL
- (2017) Thanh-Trang T. Vo et al. MOLECULAR CANCER THERAPEUTICS
- Synergistic activity of everolimus and 5-aza-2′-deoxycytidine in medullary thyroid carcinoma cell lines
- (2017) Giovanni Vitale et al. Molecular Oncology
- Clonal evolution in leukemia
- (2017) Adolfo A Ferrando et al. NATURE MEDICINE
- Tumour heterogeneity and resistance to cancer therapies
- (2017) Ibiayi Dagogo-Jack et al. Nature Reviews Clinical Oncology
- Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles
- (2017) Lorenzo Galluzzi et al. NATURE REVIEWS DRUG DISCOVERY
- Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma
- (2017) T Fujishita et al. ONCOGENE
- Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor‐Naïve Advanced Pancreatic Neuroendocrine Tumors
- (2017) Ramon Salazar et al. ONCOLOGIST
- mTORC1 activates SREBP-2 by suppressing cholesterol trafficking to lysosomes in mammalian cells
- (2017) Walaa Eid et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
- (2017) Zev A. Wainberg et al. Targeted Oncology
- Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics
- (2017) Dearbhaile C. Collins et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the Darkness
- (2017) Jordi Rodon et al. Cancer Discovery
- Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
- (2017) Eirini Pectasides et al. Cancer Discovery
- HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells
- (2017) Eva Juengel et al. Oncotarget
- Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation
- (2017) Teun van Gelder et al. Transplantation Reviews
- PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
- (2017) Zijun Y. Xu-Monette et al. Frontiers in Immunology
- Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology
- (2017) Paul Hofman Cancers
- PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
- (2017) Michele Milella et al. Scientific Reports
- TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia
- (2016) Irene M. Ghobrial et al. AMERICAN JOURNAL OF HEMATOLOGY
- Rag GTPase in amino acid signaling
- (2016) Joungmok Kim et al. AMINO ACIDS
- Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature
- (2016) KRISTEN D STARBUCK et al. ANTICANCER RESEARCH
- Monitoring of CD8(+) T-cell Activity in mTOR Inhibitor-treated Cancer Patients for Successful Immunotherapy
- (2016) Alireza Bolourian et al. ARCHIVES OF MEDICAL RESEARCH
- Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity—Diverse effects on cell growth, metabolism and cancer
- (2016) James A. McCubrey et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma
- (2016) Emmanuel Seront et al. BJU INTERNATIONAL
- Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
- (2016) Timon Vandamme et al. BRITISH JOURNAL OF CANCER
- New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease
- (2016) Mathias Lutz et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders
- (2016) Camilla Evangelisti et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation
- (2016) Matthias Waldner et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The therapeutic potential of mTOR inhibitors in breast cancer
- (2016) Linda S. Steelman et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma
- (2016) Wei Wei et al. CANCER CELL
- Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma
- (2016) Yukiyoshi Hirayama et al. CANCER SCIENCE
- The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging
- (2016) Brian K. Kennedy et al. Cell Metabolism
- Disruption of Autophagic Degradation with ROC-325 Antagonizes Renal Cell Carcinoma Pathogenesis
- (2016) Jennifer S. Carew et al. CLINICAL CANCER RESEARCH
- A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer
- (2016) Thomas Powles et al. EUROPEAN UROLOGY
- Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies
- (2016) Antonella Tramutola et al. Expert Review of Neurotherapeutics
- A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer
- (2016) Josep María del Campo et al. GYNECOLOGIC ONCOLOGY
- The TORC1-activated Proteins, p70S6K and GRB10, Regulate IL-4 Signaling and M2 Macrophage Polarization by Modulating Phosphorylation of Insulin Receptor Substrate-2
- (2016) Kristi J. Warren et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
- (2016) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- mTORC1 alters the expression of glycolytic genes by regulating KPNA2 abundances
- (2016) Xianwei Chen et al. Journal of Proteomics
- Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study
- (2016) Jacqueline A French et al. LANCET
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide
- (2016) Akinobu Matsumoto et al. NATURE
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- (2016) Vanessa S. Rodrik-Outmezguine et al. NATURE
- Mechanism of arginine sensing by CASTOR1 upstream of mTORC1
- (2016) Robert A. Saxton et al. NATURE
- The mTOR signalling cascade: paving new roads to cure neurological disease
- (2016) Peter B. Crino Nature Reviews Neurology
- mTORC1 and mTORC2 in cancer and the tumor microenvironment
- (2016) L C Kim et al. ONCOGENE
- A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
- (2016) Maria I. Carlo et al. ONCOLOGIST
- mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle
- (2016) I. Ben-Sahra et al. SCIENCE
- Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus
- (2016) Marianne Pavel et al. Targeted Oncology
- Biochemical Basis of Sestrin Physiological Activities
- (2016) Allison Ho et al. TRENDS IN BIOCHEMICAL SCIENCES
- Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling
- (2016) Lili Guo et al. TUMOR BIOLOGY
- Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235
- (2016) XIAOYU YANG et al. Oncology Letters
- Long-lasting stable disease with mTOR inhibitor treatment in a patient with a perivascular epithelioid cell tumor: A case report and literature review
- (2016) Ezequiel Flechter et al. Oncology Letters
- CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway
- (2016) Qiuyuan Wen et al. Oncotarget
- Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies
- (2016) Antonella Tramutola et al. Expert Review of Neurotherapeutics
- Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice
- (2016) Douglas E. Peterson et al. Cancer Medicine
- Therapeutic Targeting of Autophagy
- (2016) Christina G. Towers et al. EBioMedicine
- RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma
- (2015) A. Ravaud et al. ANNALS OF ONCOLOGY
- Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening
- (2015) Joanna Trelinska et al. ANTI-CANCER DRUGS
- Signalling to eIF4E in cancer
- (2015) N. Siddiqui et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Autophagy in acute leukemias: A double-edged sword with important therapeutic implications
- (2015) Cecilia Evangelisti et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data
- (2015) Karen A. Ryall et al. BIOINFORMATICS
- Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor
- (2015) Kimberly Blackwell et al. BREAST CANCER RESEARCH AND TREATMENT
- Potential therapeutic effects of mTOR inhibition in atherosclerosis
- (2015) Ammar Kurdi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders
- (2015) Kenneth Maiese BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- Autophagy in malignant transformation and cancer progression
- (2015) L. Galluzzi et al. EMBO JOURNAL
- mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer
- (2015) Feng Wei et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment
- (2015) Kazuhiro Tanaka et al. JOURNAL OF CLINICAL INVESTIGATION
- The S6K protein family in health and disease
- (2015) Mariana R. Tavares et al. LIFE SCIENCES
- Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2
- (2015) H. P. Soares et al. MOLECULAR CANCER THERAPEUTICS
- Molecular Basis of the Rapamycin Insensitivity of Target Of Rapamycin Complex 2
- (2015) Christl Gaubitz et al. MOLECULAR CELL
- Lysosomal mTORC2/PHLPP1/Akt Regulate Chaperone-Mediated Autophagy
- (2015) Esperanza Arias et al. MOLECULAR CELL
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTOR in Brain Physiology and Pathologies
- (2015) Joël Bockaert et al. PHYSIOLOGICAL REVIEWS
- mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy
- (2015) Jinghui Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Regulation of mTORC1 by PI3K signaling
- (2015) Christian C. Dibble et al. TRENDS IN CELL BIOLOGY
- Current treatment strategies for inhibiting mTOR in cancer
- (2015) Francesca Chiarini et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- The role of mTOR in lipid homeostasis and diabetes progression
- (2015) Partha Chakrabarti et al. Current Opinion in Endocrinology Diabetes and Obesity
- PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex
- (2015) P. Liu et al. Cancer Discovery
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
- (2015) P. K. Brastianos et al. Cancer Discovery
- New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
- (2015) Giuseppe Bronte et al. Oncotarget
- Double autophagy modulators reduce 2-deoxyglucose uptake in sarcoma patients
- (2015) Mau-Shin Chi et al. Oncotarget
- The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells
- (2015) Carolina Simioni et al. Oncotarget
- Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort
- (2015) Kwan-Hwa Chi et al. Oncotarget
- Hydroxychloroquine Destabilizes Phospho-S6 in Human Renal Carcinoma Cells
- (2015) Hyung-Ok Lee et al. PLoS One
- Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment
- (2015) Alberto M. Martelli et al. Oncotarget
- Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades
- (2015) James Andrew McCubrey et al. Oncotarget
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
- (2015) James Andrew McCubrey et al. Oncotarget
- Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
- (2015) Burhan Hassan et al. Oncotarget
- Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
- (2014) H. S. Rugo et al. ANNALS OF ONCOLOGY
- Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer
- (2014) I. Treilleux et al. ANNALS OF ONCOLOGY
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
- (2014) M. Piccart et al. ANNALS OF ONCOLOGY
- Combined MTOR and autophagy inhibition
- (2014) Reshma Rangwala et al. Autophagy
- Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art
- (2014) J. Michael Randall et al. CANCER AND METASTASIS REVIEWS
- FoxO Transcription Factors Promote AKT Ser473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI3K–AKT Pathway
- (2014) Aifu Lin et al. CANCER RESEARCH
- Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors
- (2014) Ozgur Sahin et al. CELL RESEARCH
- Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
- (2014) M. H. Voss et al. CLINICAL CANCER RESEARCH
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
- (2014) K. P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- PIKKs — the solenoid nest where partners and kinases meet
- (2014) Domagoj Baretić et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation
- (2014) Yukiko Hasumi et al. HUMAN MOLECULAR GENETICS
- Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
- (2014) Carolyn D. Britten et al. INVESTIGATIONAL NEW DRUGS
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Fabrice André et al. LANCET ONCOLOGY
- Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study
- (2014) David Neal Franz et al. LANCET ONCOLOGY
- Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma
- (2014) D. Cirstea et al. MOLECULAR CANCER THERAPEUTICS
- Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance
- (2014) E. Rozengurt et al. MOLECULAR CANCER THERAPEUTICS
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
- (2014) Nikhil Wagle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1
- (2014) Sharmila Mallya et al. PLoS One
- The structural basis for mTOR function
- (2014) Domagoj Baretić et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Regulation of mTORC1 by amino acids
- (2014) Liron Bar-Peled et al. TRENDS IN CELL BIOLOGY
- A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
- (2014) B. C. Grabiner et al. Cancer Discovery
- Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
- (2014) N. Wagle et al. Cancer Discovery
- PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation
- (2013) E Seront et al. BRITISH JOURNAL OF CANCER
- Metabolic complications with the use of mTOR inhibitors for cancer therapy
- (2013) Shanthi Sivendran et al. CANCER TREATMENT REVIEWS
- p53/TAp63 and AKT Regulate Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling through Two Independent Parallel Pathways in the Presence of DNA Damage
- (2013) Maren Cam et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation
- (2013) Claire L. Cope et al. JOURNAL OF CELL SCIENCE
- Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
- (2013) John J Bissler et al. LANCET
- MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer
- (2013) Bing Li et al. LUNG CANCER
- Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis
- (2013) Pengda Liu et al. NATURE CELL BIOLOGY
- Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma
- (2013) D. A. Krueger et al. NEUROLOGY
- Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors
- (2013) G S Ducker et al. ONCOGENE
- Pancreatic tumours escape from translational control through 4E-BP1 loss
- (2013) Y Martineau et al. ONCOGENE
- Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
- (2013) Jiri Polivka et al. PHARMACOLOGY & THERAPEUTICS
- Coordinate Autophagy and mTOR Pathway Inhibition Enhances Cell Death in Melanoma
- (2013) Xiaoqi Xie et al. PLoS One
- PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1
- (2013) H. Ebi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1
- (2013) I. Ben-Sahra et al. SCIENCE
- mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin
- (2013) S. A. Kang et al. SCIENCE
- A Tumor Suppressor Complex with GAP Activity for the Rag GTPases That Signal Amino Acid Sufficiency to mTORC1
- (2013) L. Bar-Peled et al. SCIENCE
- Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells
- (2013) P. Casado et al. Science Signaling
- eIF4E/4E-BP Ratio Predicts the Efficacy of mTOR Targeted Therapies
- (2012) T. Alain et al. CANCER RESEARCH
- Ragulator Is a GEF for the Rag GTPases that Signal Amino Acid Levels to mTORC1
- (2012) Liron Bar-Peled et al. CELL
- Functional Assessment ofTSC2 Variants Identified in Individuals with Tuberous Sclerosis Complex
- (2012) Marianne Hoogeveen-Westerveld et al. HUMAN MUTATION
- Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: Clinical and molecular correlates
- (2012) Mark A. Dickson et al. INTERNATIONAL JOURNAL OF CANCER
- The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/ Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance
- (2012) Bao Hoang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms
- (2012) Ludovica Ciuffreda et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
- (2012) David Neal Franz et al. LANCET
- Combined therapeutic application of mTOR inhibitor and vitamin D3 for inflammatory bone destruction of rheumatoid arthritis
- (2012) Tae-Hwan Kim et al. MEDICAL HYPOTHESES
- mTOR inhibition with rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes
- (2012) Maria J. Pereira et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- The translational landscape of mTOR signalling steers cancer initiation and metastasis
- (2012) Andrew C. Hsieh et al. NATURE
- Autophagy Suppresses RIP Kinase-Dependent Necrosis Enabling Survival to mTOR Inhibition
- (2012) Kevin Bray et al. PLoS One
- Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
- (2012) D. W. Lamming et al. SCIENCE
- Genome Sequencing Identifies a Basis for Everolimus Sensitivity
- (2012) G. Iyer et al. SCIENCE
- Successful treatment with the mTOR inhibitor everolimus in a patient with Perivascular epithelioid cell tumor
- (2012) Constantine Gennatas et al. World Journal of Surgical Oncology
- Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney
- (2011) Laura R. Pearce et al. BIOCHEMICAL JOURNAL
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Activation of mTORC2 by Association with the Ribosome
- (2011) Vittoria Zinzalla et al. CELL
- The mTOR (Mammalian Target of Rapamycin) Kinase Maintains Integrity of mTOR Complex 2
- (2011) Chien-Hung Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
- (2011) Marianne E Pavel et al. LANCET
- Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia
- (2011) C Evangelisti et al. LEUKEMIA
- Cell-Type-Dependent Regulation of mTORC1 by REDD1 and the Tumor Suppressors TSC1/TSC2 and LKB1 in Response to Hypoxia
- (2011) N. C. Wolff et al. MOLECULAR AND CELLULAR BIOLOGY
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTORC1 Senses Lysosomal Amino Acids Through an Inside-Out Mechanism That Requires the Vacuolar H+-ATPase
- (2011) R. Zoncu et al. SCIENCE
- Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling
- (2011) Y. Yu et al. SCIENCE
- The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
- (2011) P. P. Hsu et al. SCIENCE
- The ATM protein kinase and cellular redox signaling: beyond the DNA damage response
- (2011) Scott Ditch et al. TRENDS IN BIOCHEMICAL SCIENCES
- mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
- (2011) V. S. Rodrik-Outmezguine et al. Cancer Discovery
- Insulin-induced serine phosphorylation of IRS-2 via ERK1/2 and mTOR: studies on the function of Ser675 and Ser907
- (2010) Louise Fritsche et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa
- (2010) A. Italiano et al. ANNALS OF ONCOLOGY
- Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells
- (2010) Sven A. Lang et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids
- (2010) Yasemin Sancak et al. CELL
- Multi-mechanisms are involved in reactive oxygen species regulation of mTORC1 signaling
- (2010) Ming Li et al. CELLULAR SIGNALLING
- Requirement of the mTOR Kinase for the Regulation of Maf1 Phosphorylation and Control of RNA Polymerase III-dependent Transcription in Cancer Cells
- (2010) Boris Shor et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Tti1 and Tel2 Are Critical Factors in Mammalian Target of Rapamycin Complex Assembly
- (2010) Takeshi Kaizuka et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors
- (2010) Andrew J. Wagner et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
- (2010) Darcy A. Krueger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic targeting of mTOR in tuberous sclerosis
- (2009) Julian R. Sampson BIOCHEMICAL SOCIETY TRANSACTIONS
- Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia
- (2009) F. Chiarini et al. CANCER RESEARCH
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
- (2009) Timothy R. Peterson et al. CELL
- REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A–DDB1 ubiquitin ligase
- (2009) Samiksha Katiyar et al. EMBO REPORTS
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway
- (2009) Edoardo Missiaglia et al. JOURNAL OF CLINICAL ONCOLOGY
- Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
- (2009) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1
- (2009) C. C. Dibble et al. MOLECULAR AND CELLULAR BIOLOGY
- Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling
- (2009) M. A. Lopez-Lago et al. MOLECULAR AND CELLULAR BIOLOGY
- The nuts and bolts of AGC protein kinases
- (2009) Laura R. Pearce et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2
- (2009) Y. Hasumi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mTORC1 Phosphorylates the ULK1-mAtg13-FIP200 Autophagy Regulatory Complex
- (2009) E. Y. Chan Science Signaling
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis
- (2008) B. Shor et al. CANCER RESEARCH
- Oncogenic MAPK Signaling Stimulates mTORC1 Activity by Promoting RSK-Mediated Raptor Phosphorylation
- (2008) Audrey Carrière et al. CURRENT BIOLOGY
- Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
- (2008) Arkaitz Carracedo et al. JOURNAL OF CLINICAL INVESTIGATION
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
- (2008) S Park et al. LEUKEMIA
- AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
- (2008) Dana M. Gwinn et al. MOLECULAR CELL
- Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
- (2008) A. Y. Choo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma
- (2008) Tim F Cloughesy et al. PLOS MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started